FINANCINGS
Aduro Biotech Inc. filed with the SEC seeking to raise up to $86.25 million, including overallotments, in its IPO.
Aeterna Zentaris Inc. priced its public offering with net proceeds expected to be approximately $34.5 million.
Allergen Research Corp. said it completed an $80 million series B financing.
Ampliphi Biosciences Corp. is selling common stock and warrants to raise approximately $13 million in a private placement.
Biolinerx Ltd. closed its public offering of 14.375 million American depositary shares for gross proceeds of $28.75 million.
Collegium Pharmaceutical Inc. raised $50 million in a financing to advance its lead abuse-deterrent product candidate.
Curevac GmbH received a $52 million equity investment from the Bill & Melinda Gates Foundation plus an additional $24 million equity investment from Dievini Hopp Biotech.
Horizon Pharma plc priced its offering of $350 million senior notes due 2022 in a private placement.
Intra-Cellular Therapies Inc. completed its public offering with net proceeds of about $121.4 million.
IP Group plc is raising $193 million in an oversubscribed placing, enabling it to increase investments in its portfolio of academic spinouts.
Kura Oncology Inc. completed a private placement for gross proceeds of approximately $60 million.
Kythera Biopharmaceuticals Inc. priced its public offering for gross proceeds of approximately $125 million.
Nordic Nanovector ASA is seeking $48.7 million in what would be the Nordic region's first significant biotech IPO of 2015.
Phasebio Pharmaceuticals Inc. raised $40 million in a series C round.
Portola Pharmaceuticals Inc. is raising about $99.6 million in a public offering.
Summit Therapeutics plc closed its IPO of 3.5 million American depositary shares (ADSs) at $9.90 per ADS.
Tesaro Inc. closed its public offering of common stock for estimated net proceeds of about $179.7 million.
Tetraphase Pharmaceuticals Inc. priced a public offering for gross proceeds of about $150 million.
Tobira Therapeutics Inc. said it completed a $13 million convertible note financing.
DEALS
Calithera Biosciences Inc. signed a global license to a portfolio of hexokinase II inhibitors developed by Transtech Pharma LLC and affiliate High Point Pharmaceuticals LLC.
Cellectis SA is collaborating/with Modiquest Research BV to generate monoclonal antibodies against targets selected by Cellectis.
Concordia Healthcare Corp. is acquiring Covis Pharma Sàrl and its Covis Injectables Sàrl unit for $1.2 billion in cash.
Ember Therapeutics Inc. and Mariel Therapeutics Inc. are merging with the combined entity to be named Ember Therapeutics.
Endo International plc has made an unsolicited $11 billion cash and shares bid for Salix Pharmaceuticals Inc.
Epizyme Inc. reacquired global rights to its EZH2 program, including EPZ-6438, from partner Eisai Co. Ltd.
Inmed Pharmaceuticals Inc. formed a collaboration with the University of Debrecen, Hungary, to develop phytocannabinoid-based therapies to treat ocular allergic symptoms.
Sucampo Pharmaceuticals Inc. is returning to R-Tech Ueno Ltd. all licenses for the eye drug unoprostone isopropyl.
Targacept Inc. and Catalyst Biosciences Inc. entered a reverse merger with Catalyst gaining a public listing – the anticipated ticker is CBIO.
. . . AND MORE
Astellas Pharma Inc. said the FDA approved Cresemba, an antifungal to treat adults with invasive aspergillosis and invasive mucormycosis, both rare infections.
The FDA approved Sandoz Inc.'s Zarxio, a biosimilar to Amgen Inc.'s Neupogen (filgrastim).
Radius Health Inc. obtained full global rights to develop RAD 1901 for various therapies, including metastatic breast cancer, from Eisai Co. Ltd.